{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": false,
  "explanation": "Table displaying demographic and clinical characteristics of participants split into two arms: Recombinant Vaccine (N=279,400) and Standard-Dose Vaccine (N=395,852), with counts and percentages for sex, race/ethnicity, coexisting illnesses, and prior influenza vaccination. does not support the claim because the table only labels the arms as \u201cRecombinant Vaccine\u201d and \u201cStandard-Dose Vaccine\u201d without specifying Flublok or Fluarix, so it does not directly show that Flublok was compared against Fluarix. Note: No brand names are provided and the table text is generic; it is unclear which vaccines correspond to Flublok or Fluarix.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "Table displaying demographic and clinical characteristics of participants split into two arms: Recombinant Vaccine (N=279,400) and Standard-Dose Vaccine (N=395,852), with counts and percentages for sex, race/ethnicity, coexisting illnesses, and prior influenza vaccination.",
    "evidence_found": null,
    "reasoning": "does not support the claim because the table only labels the arms as \u201cRecombinant Vaccine\u201d and \u201cStandard-Dose Vaccine\u201d without specifying Flublok or Fluarix, so it does not directly show that Flublok was compared against Fluarix.",
    "confidence_notes": "No brand names are provided and the table text is generic; it is unclear which vaccines correspond to Flublok or Fluarix."
  }
}